What is Lexeo Therapeutics, Inc. Common Stock (LXEO) stock price today?

Lexeo Therapeutics, Inc. Common Stock (LXEO) currently trades at $5.70 per share. The stock has a market capitalization of $416.74M and a P/E ratio of —x.

Is LXEO stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Lexeo Therapeutics, Inc. Common Stock has a Smart Value Score of 31/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -1.95.

Is Lexeo Therapeutics, Inc. Common Stock financially healthy?

Lexeo Therapeutics, Inc. Common Stock's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -1.95 places it in the distress.

LXEO

Lexeo Therapeutics, Inc. Common Stock

NASDAQ: LXEO · HEALTHCARE · BIOTECHNOLOGY

$5.70

+0.26% today

Updated 2026-04-30

Market cap

$416.74M

P/E ratio

—

P/S ratio

478.26x

EPS (TTM)

$-1.86

Dividend yield

—

52W range

$2 – $11

Volume

0.9M

Market cap

$416.74M

P/E ratio

—

P/S ratio

478.26x

EPS (TTM)

$-1.86

Dividend yield

—

52W range

$2 – $11

Volume

0.9M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

6.5

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-2.0

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$19.64

+244.86%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

2 Strong Buy9 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.07x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -1.95 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-20.08M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$654000.00	$0.00	$0.00	$0.00	$0.00
Net income	$-59.28M	$-66.39M	$-98.33M	$-99.96M	$-20.92M
EPS	—	—	—	—	$-1.86
Free cash flow	$-55.46M	$-59.66M	$-81.63M	$-98.96M	$-20.08M
Profit margin	-9,063.76%	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
LXEO	$416.74M	31	4.3	3.0	5.0	6.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Lexeo Therapeutics, Inc. Common Stock trades at $5.70. Our Smart Value Score of 31/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -1.95, it sits in the distress.

Frequently asked questions

What is Lexeo Therapeutics, Inc. Common Stock's stock price?

Lexeo Therapeutics, Inc. Common Stock (LXEO) trades at $5.70.

Is Lexeo Therapeutics, Inc. Common Stock overvalued?

Smart Value Score 31/100 (Grade F, Strong Sell).

What is the price target of Lexeo Therapeutics, Inc. Common Stock (LXEO)?

The analyst target price is $19.64, representing +244.9% upside from the current price of $5.70.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-1.95 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.lexeotx.com

Quick metrics

P/S ratio478.26x

ROE-55.00%

Beta2.00

50D MA$6.33

200D MA$7.03

Shares out0.07B

Float0.04B

Short ratio—

Avg volume0.9M

Performance

1 week-11.14%

1 month+6.74%

3 months-24.40%

YTD-43.35%

1 year—

3 years—

5 years—

Compare

LXEO vs LLY →LXEO vs JNJ →LXEO vs ABBV →Stock screener →